Interferon beta-1a in relapsing-remitting multiple sclerosis

被引：2
|
作者：
Blumhardt, L [1 ]
机构：
[1] Univ Nottingham, Div Clin Neurol, Nottingham NG7 2UH, England
来源：
HOSPITAL MEDICINE | 1999年 / 60卷 / 03期
关键词：
D O I：
10.12968/hosp.1999.60.3.1065
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The accumulated results from multiple trials have unequivocally demonstrated beneficial effects of interferon beta-1a on disease activity in relapsing-remitting multiple sclerosis, both for clinical and magnetic resonance endpoints. New data suggest that low doses administered once weekly ore relatively ineffective and that higher, more Frequent doses are required for optimal benefit.
引用
收藏
页码：192 / 195
页数：4
相关论文
共 50 条
  • [31] Estimating Net Health Benefits of Intramuscular Interferon Beta-1a and Fingolimod in Treating Patients with Relapsing-Remitting Multiple Sclerosis
    Szabo, Shelagh
    Dembek, Carole
    Moore, Peter
    White, Leigh Ann
    Wijaya, Hardy
    Levy, Adrian
    [J]. NEUROLOGY, 2012, 78
  • [32] Efficacy and safety of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis: Further outcomes from the IMPROVE study
    De Stefano, Nicola
    Sormani, Maria Pia
    Stubinski, Bettina
    Blevins, Gregg
    Drulovic, Jelena S.
    Issard, Delphine
    Shotekov, Penko
    Gasperini, Claudio
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2012, 312 (1-2) : 97 - 101
  • [33] ESTIMATING NET HEALTH BENEFITS OF INTRAMUSCULAR INTERFERON BETA-1A AND FINGOLIMOD IN TREATING PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Szabo, S. M.
    Dembek, C.
    Moore, P.
    White, L. A.
    Wijaya, H.
    Levy, A. R.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A317 - A317
  • [34] COST-EFFECTIVENESS OF FINGOLIMOD, TERIFLUNOMIDE, DIMETHYL FUMARATE AND INTRAMUSCULAR INTERFERON BETA-1A IN RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Zhang, X.
    Hay, J. W.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A59 - A60
  • [35] Interferon Beta Use and Disability Prevention in Relapsing-Remitting Multiple Sclerosis
    Greenberg, Benjamin M.
    Balcer, Laura
    Calabresi, Peter A.
    Cree, Bruce
    Cross, Anne
    Frohman, Teresa
    Gold, Ralf
    Havrdova, Eva
    Hemmer, Bernhard
    Kieseier, Bernd C.
    Lisak, Robert
    Miller, Aaron
    Racke, Michael K.
    Steinman, Lawrence
    Stuve, Olaf
    Wiendl, Heinz
    Frohman, Elliot
    [J]. JAMA NEUROLOGY, 2013, 70 (02) : 248 - 251
  • [36] Impact of discontinuing interferon beta in patients with relapsing-remitting multiple sclerosis
    Agiela, Mabroka I. M.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (06) : NP5 - NP5
  • [37] Predicting beta-interferon failure in relapsing-remitting multiple sclerosis
    O'Rourke, K.
    Walsh, C.
    Antonelli, G.
    Hutchinson, M.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2007, 13 (03) : 336 - 342
  • [38] Interferon-beta and disability progression in relapsing-remitting multiple sclerosis
    Drulovic, Jelena
    Kostic, Jelena
    Mesaros, Sarlota
    Basuroski, Irena Dujmovic
    Stojsavljevic, Nebojsa
    Kisic-Tepavcevic, Darija
    Pekmezovic, Tatjana
    [J]. CLINICAL NEUROLOGY AND NEUROSURGERY, 2013, 115 : S65 - S69
  • [39] Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis
    Cocco, Eleonora
    Marrosu, Maria Giovanna
    [J]. THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2015, 11 : 759 - 766
  • [40] The innovative development in interferon beta treatments of relapsing-remitting multiple sclerosis
    Madsen, Claus
    [J]. BRAIN AND BEHAVIOR, 2017, 7 (06):
12345